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Abstract
Patients often discontinue treatment in a clinical trial because their health condition is not improving. Consequently,
the patients still in the study at the end of the trial have better health outcomes on average than the initial patient
population would have had if every patient had completed the trial. If we only analyze the patients who complete
the trial, then this “missing data problem” biases the estimator of a medication’s efficacy because study outcomes are
missing not at random (MNAR). One way to overcome this problem - the trimmed means approach for missing data -
sets missing values as slightly worse than the worst observed outcome and then trims away a fraction of the distribution
from each treatment arm before calculating differences in treatment efficacy (Permutt 2017, Pharmaceutical statistics
16.1: 20-28). In this paper we derive sufficient and necessary conditions for when this approach can identify the average
population treatment effect in the presence of MNAR data. Numerical studies show the trimmed means approach’s
ability to effectively estimate treatment efficacy when data are MNAR and missingness is strongly associated with an
unfavorable outcome, but trimmed means fail when data are missing at random (MAR) when the better approach
would be to multiply impute the missing values. If the reasons for discontinuation in a clinical trial are known analysts
can improve estimates with a combination of multiple imputation (MI) and the trimmed means approach when the
assumptions of each missing data mechanism hold. When the assumptions are justifiable, using trimmed means can
help identify treatment effects notwithstanding MNAR data.
Keywords: Missing Data, Trimmed Means, Clinical Trials, Estimand
1 Introduction
Restricting statistical analysis to patients that complete a clinical trial can lead to biased results [1]. Patients with
unfavorable endpoints often discontinue the trial prematurely and thus the remaining patients no longer provide a truly
representative sample of patients, even if the original sample did. This situation can be viewed as a missing data problem
– the endpoints are not measured for the patients who have left the study and are thus labeled as missing. There is no
consensus on how best to adjust a statistical analysis for missing data. This is due in part because the reason for missing
data impacts the choice of analytical methods to use. The best understood situation is when the data are missing at
random (MAR) [2]. This means that one observes all the data necessary to explain the missingness in the data - i.e. the
missing values themselves did not contribute to the fact that they are missing. This, of course, is not only an untestable
assumption, but in many settings, it is an unrealistic one. Its complementary situation, when data are missing not at
random (MNAR), occurs in clinical trials. An example of this is trials of chronic pain, where subjects are more likely to
leave the study if they experience little or no decrease in pain. Consequently, the outcomes of those who complete the
study differs from those who do not, often even when accounting for observed information. In these situations, ignoring
the violations of the assumptions underpinning popular missing data methods designed for MAR data, such as multiple
imputation [3] and inverse probability weighting [4], leads to biases that make the analyses inadequate and of little scientific
value.
The paucity of data analytic methods for when the data are MNAR may contribute to the widespread use of inappro-
priate methods. The National Research Council (NRC) report on missing data suggests two general paths forward when
data are MNAR: Selection Models and Pattern-Mixture Models [5]. Both of these models are limited in that they rely
on parameters that cannot be inferred from the observed data. Therefore, identification of treatment effects using these
models is not possible. This limitation is emphasized by Little [6] who highlights that all MNAR models are subject to a
fundamental lack of identification. The shadow variable approach of Miao & Tchetgen Tchetgen can identify causal effects
under MNAR [7]; however, it relies on the presence of a surrogate outcome - a shadow variable - that is closely related to
the missing outcome and unrelated to why the missing outcome is unobserved. One may not observe such a variable in the
clinical trial setting. Jump to reference imputation [8] is a popular approach to handling MNAR data where the missing
outcomes of patients in the experimental treatment arm are imputed using observed outcomes from the placebo arm. The
logic of this approach makes intuitive sense, in the experimental arm MNAR dropouts have worse outcomes than those
who complete the study. So to reflect this difference one can leverage the worse outcomes of reference/placebo arm for
imputations of experimental dropouts. The main drawback for the MNAR setting is that missing outcomes in the placebo
arm are imputed by placebo completers which effectively assumes MAR. If reference arm dropouts are MNAR, then
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placebo imputations may be optimistic and the treatment effect can be underestimated. Especially in placebo-controlled
trials, one generally expects more lack of efficacy dropouts in the reference arm which could be problematic for jump to
reference unless initial measurements leveraged for imputations reveal the poor outcome trajectory.
The “trimmed means approach” for missing data was first introduced by Li and Permutt [9]. The method is designed
for settings where missing values can be assumed to be poor health outcomes that are the continuous endpoints of the
study; precisely the example introduced above. We focus on this method in the remainder of the paper. The trimmed
means approach is simple to implement in a comparative trial. The final statistic is the arithmetic mean after trimming
the poor performing parts of the distribution in each arm of the study, after assigning a value to the missing outcomes
that is worse than the worst observed outcome. Applying this approach only requires the ability to assign a rank to all
outcomes and ranks missing outcomes at the tail end of the distribution prior to trimming. The trimmed means approach
can be extended to include covariates such as in an ANCOVA and can be applied in mixed models for repeated measures
(MMRM) [10]. The trimmed-means-approach was designed to estimate an estimand different than most standard analyses.
Instead of estimating treatment difference in the whole study population, the approach estimates the treatment difference
in a subset of the best performing patients since those performing poorly are trimmed out of the analysis. As a result,
some of the data is lost, and that is the price one pays for obtaining an analysis that accommodates MNAR data. The
trimmed-means-approach was evaluated under various missing data generating mechanisms [11], which reveals some of its
limitations.
The rest of the paper concentrates on extending the utility of the trimmed-means-approach for missing data. Section
2 describes the trimmed means approach and extends its use to a combination with multiple imputation. Section 3
discusses the estimand and provides a proof for settings under which the trimmed means approach can identify the
population treatment effect. Section 4 evaluates the finite sample properties of the approach in a numerical study under
various missing data mechanisms. Section 5 provides recommendations on how to apply the approach in the context of a
randomized clinical trial for a chronic pain medication. Section 6 concludes the article with a discussion.
2 Statistical Methods
2.1 The Trimmed Means Estimator
In 2017, Permutt and Li [9] introduced the trimmed means estimator. They provide a thorough motivation of the approach
as well as how to implement it in practice. Mehrotra et al. demonstrate an implementation of the approach in SAS [12].
This approach does not rely on any parametric model or imputation of the missing values; it only depends on the ability to
rank outcomes. The trimmed means approach for missing data utilizes one sided trimmed means. Consider a continuous
outcome Yi for observation i. The one sided trimmed mean is an L-estimator defined as:
µˆT =
1
nT
n∑
i:Yi>Fˆ−1(α)
Yi
The above is simply the average of the observations that fall above the quantile Fˆ−1(α) of the empirical distribution
function of Yi where α represents the proportion of trimmed outcomes. For example, α = 0.3 represents trimming away
the bottom 30% of the distribution. Here, nT =
∑n
i=1 1(Yi > Fˆ
−1(α)) is the sample size after trimming. The expectation
of the trimmed mean is the population trimmed mean:
µT = E[Y |Y > F−1(α)] = 1
1− α
∫ ∞
F−1(α)
yf(y)dy
Note that for this example above, poor outcomes correspond to low values of Y , so the lower part of the distribution
is trimmed. This could be switched based on the clinical context. For example, in pain trials a decrease in pain intensity
is a good outcome, so one would rather trim away the upper part of the distribution.
To implement this approach, first consider three observed variables: A a binary indicator for treatment, R a binary
missing data indicator, and the clinical outcome Y which is a continuous value when R = 1 and is missing when R = 0.
Operationally, the first step of the trimmed means approach is to remove the missing data by ranking all missing outcomes
as slightly worse than the poorest observed outcome in the trial. To do so one defines a new outcome denoted by U for
each subject i:
Ui =
{
Yi if Ri = 1
min(Y)−  if Ri = 0
for  > 0
Note the above corresponds to low values representing poor outcomes. If high values of the outcome reflected poor
values then if R = 0 the missing outcomes would be set to max(Y )+ . After ranking, α proportion of each treatment arm
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is trimmed away from the end of the distribution of U associated with poor outcomes. The analyst has some flexibility
in determining α, the proportion of data trimmed from each distribution, before calculating the treatment effect. This
value can be fixed a priori with a value of α chosen that anticipates the amount of missing data. Alternatively, trimming
can be adaptive and chosen to be the maximum between the proportions of missing data in each arm. Thus the values
that the missing observations were set to are never actually used in the analysis, but do serve the important function
of informing the quantiles at which each distribution is to be trimmed. After trimming, then calculate the mean of the
remaining 100× (1− α)% observations in each arm µˆT1 and µˆT0. The final estimate is obtained by taking the difference
of these trimmed means between each arm: µˆT∆ = µˆT1 − µˆT0.
Inference can be conducted via a permutation test that conditions on the observed data and randomly permutes the
treatment assignments. The resulting permutation distribution of treatment differences formed under the null hypothesis
can be used to determine significant differences and confidence intervals. To reject the null hypothesis of no treatment
difference, the point estimate should fall above the upper 2.5th percentile of the permutation distribution. If µˆT∆ is
the treatment difference calculated after trimming, a 95% confidence interval can be constructed by adding the 97.5th
and 2.5th percentiles of the permutation distribution to µT∆. This can be generalized for any significance level γ such
that
(
µˆT∆ − yγ/2, µˆT∆ + y1−γ/2
)
yields a (1 − γ)% confidence interval where yγ is the γ percentile of the permutation
distribution. Since these confidence intervals are constructed using the permutation distribution generated under the null
hypothesis, the intervals will be conservative when the null hypothesis is false [13].
2.2 Combining Trimmed Means with Multiple Imputation
In well conducted clinical trials, the reason for study discontinuation is collected for each patient who drops out of the
study. Treating certain types of dropout as poor outcomes and ranking them at the low end of the distribution, as the
trimmed means approach does, would lead to biases. Knowing the reason for dropping out of a study, and using that
information, should lead to more precise analyses. To that end, consider the expanded indicator:
R =

r1 if Y observed
r2 if MAR or MCAR
r3 if MNAR
Assume the complete data of Y is partitioned into the observed and missing components as follows Y = [Yr1 , Yr2 , Yr3 ]
which denote the observed, missing at random, and missing not at random components of Y respectively. Here we propose
imputing Yr2 and trimming Yr3 . We can perform multiple imputation of Yr2 when the conditional distribution f(Yr2 |Yr1 =
yr1 , A,X) is a valid imputation model given the MAR assumption. Here yr1 denotes the observed outcomes, A is the
treatment assignment, andX is a matrix of auxiliary covariates that may or may not be available and of use for imputations.
Using this conditional distribution, one can draw m samples for the MAR and MCAR data Y (1)r2 , Y
(2)
r2 , . . . , Y
(m)
r2 to derive
a set of data that is now complete for Yr2 where missing values Yr3 remain. Let µˆT∆ = µˆT∆ (Yr1 , Yr2 ,1(R = r3)) denote
the trimmed means statistic given that complete data on Yr2 were available. Note we do not need to observe Yr3 since the
trimmed means approach will trim these observations out of the analysis. Multiple imputation relies on the asymptotically
normal distribution of µˆT∆, which applies to the trimmed mean [14]. Since data on Yr2 are missing, the imputed data are
utilized to calculate trimmed means estimates of the form µˆ(`)T∆ = µˆT∆
(
Yr1 , Y
(`)
r2 ,1(R = r3)
)
for the m imputed datasets.
Lastly, we Rubin’s rules [3] to summarize the results of the trimmed means applied to each partially imputed dataset.
µ¯T∆ =
1
m
m∑
`=1
µ
(`)
T∆ =
1
m
m∑
`=1
µ
(`)
T1 − µ(`)T0
V ar(µ¯T∆) =
1
m
m∑
`=1
(σ(`))2 +
(
1 +
1
m
)(
1
m− 1
m∑
`=1
(
µ
(`)
∆ − µ¯T∆
)2)
Where σ(`) is the estimated standard error of the trimmed means estimate in the `th imputed dataset. This combination
approach is only valid if all unobserved values of Yr3 fall below the quantile of the distributions that are trimmed, a condition
discussed in the subsequent section.
3 Properties of the Estimand
3.1 Equivalence to the Population Treatment Effect
We focus on a randomized clinical trial, where the estimand of interest is the treatment difference in the population means
of a clinical endpoint. Consider counterfactual outcomes Ya where a ∈ 0, 1 indicates potential treatment assignments.
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In addition, A ∈ 0, 1 is the binary indicator for observed treatment in the trial. Denote Ua as the counterfactual
version of the composite outcome defined in section 2. The trimmed means estimand is most similar to a composite
estimand, using the terminology of the ICH E9 addendum [15]. The trimmed means estimand in counterfactual notation
is E[U1|U1 > F−1U1 (α)] − E[U0|U0 > F−1U0 (α)] where F−1Ua (α) represents the inverse cdf of the counterfactual distributions
of Ua evaluated at α. This is a unique estimand defined for a sub-population of the trial, interpreted as the difference
between treatments in endpoint means in the best 100 × (1 − α)% of patients from each arm. This is not, however, the
treatment effect among all randomized patients.
The advantage of the trimmed means approach’s composite estimand is that it gives us a strategy for handling the
missing data; however, the main drawback of using a composite estimand is that the clinical relevance can be unclear.
In may be difficult and unfamiliar to interpret an estimated treatment effect in the best 100 × (1 − α)% of patients as
compared to an estimate of efficacy for all patients in a particular indication. The estimand for treatment efficacy in the
population from which all randomized patients are drawn is the difference in counterfactual means E[Y1]−E[Y0], however
using the trimmed means approach only the difference in trimmed means of the composite outcomes U1 and U0 are
estimated. Herein, the sufficient and necessary conditions under which the trimmed means estimand and the population
estimand for treatment effect are identical are formalized.
Theorem 1. If the outcomes among the treated and untreated are identically distributed relative to a shift and all unob-
served values fall below the trim, then the treatment difference estimated by the trimmed means approach is equivalent to
the treatment difference in the population, i.e.:
E[U1|U1 > F−1U1 (α)]− E[U0|U0 > F−1U0 (α)] = E[Y1]− E[Y0]
The proof is given in the appendix.
Theorem 1 uses the following two conditions in order to prove the equality of the trimmed means estimand and
treatment difference in the whole population.
1. Location family assumption. The distribution of potential outcomes had the patient taken the experimental
treatment Y1 ∼ f1(y) is in the same location family as the distribution of potential outcomes had the patient taken
the reference treatment Y0 ∼ f0(y). Consider some constant ∆ then:
f0(y) = f1(y + ∆)
2. Strong MNAR assumption. All missing values fall below the point at which the distributions are trimmed.
Explicitly, the strong MNAR assumption states:
Ya|Ra = 0 < F−1a (α)
The strong MNAR assumption ensures that the composite outcome Ua is trimmed at the same value as Ya for all percentiles
above the maximum rate of missing data between the two arms, i.e. F−1Ua (α) = F
−1
a (α)∀α : α > Pr[Ra = 0]. It also
guarantees that the untrimmed distribution of Ua is identical to that of Ya.
If Y1 and Y0 can be identified from the observed data, then the trimmed means approach can estimate the causal
estimand of treatment effect in the population given the above two assumptions as shown:
E[Y1]− E[Y0] = E[Y1|Y1 > F−11 (α)]− E[Y0|Y0 > F−10 (α)] (1)
= E[U1|U1 > F−1U1 (α)]− E[U0|U0 > F−1U0 (α)] (2)
= E[U1|U1 > F−1U1 (α), A = 1]− E[U0|U0 > F−1U0 (α), , A = 0]
= E[U |U > F−1U1 (α), A = 1]− E[U0|U0 > F−1U0 (α), , A = 0]
The location family assumption makes the average difference of the entire population of counterfactuals equivalent to
the difference in the sub-population of counterfactuals that are not trimmed (1). The strong MNAR assumption makes the
trimmed means of the counterfactuals equivalent to the trimmed means of the composite outcome (2). Then randomization
and consistency allow us to identify the counterfactuals from the observed data [16]. Note that using Theorem 1 only the
difference in the counterfactual means can be recovered, albeit with a smaller sample size than if there were no MNAR
data. One cannot accurately estimate the marginal means of Y1 and Y0 in the presence of MNAR data.
Theorem 2. If the difference in untrimmed means between two counterfactual distributions is equivalent to the difference
in one sided trimmed means for all percentiles,
E[Y1|Y1 > F−11 (α)]− E[Y0|Y0 > F−10 (α)] = E[Y1]− E[Y0] = ∆ ∀α(0, 1)
then the counterfactual distributions are a location shift of one another
f0(y) = f1(y + ∆)
4
Proof is given in the appendix.
Theorem 2 demonstrates that using the trimmed means approach to estimate the population treatment effect is only
relevant for treatments with an additive effect. For all possible α, the difference in trimmed means and the population
mean are equivalent if and only if the distributions being compared are a location shift of one another. There are conditions
where the difference in trimmed means and population means are equivalent when the strong MNAR assumption is not
true (i.e. the MCAR case). Thus, theorem 2 reveals that the location family assumption is a sufficient and necessary
condition, while the strong MNAR assumption is only a sufficient condition for the equivalence of the estimands.
3.2 Intercurrent Events
Theorem 1 extends the utility of the trimmed means approach by proving under what assumptions one can estimate the
estimand representing the treatment effect based on all randomized patients rather than a subset of the best performing
patients. It is important to discuss how this result fits into the estimand framework outlined in the ICH E9 addendum
[14]. The trimmed means approach is a statistical analysis that specifies how to deal with missing data, not necessarily a
particular strategy to deal with intercurrent events (IE), which may often, but do not deterministically, lead to missing
data. The IE strategy depends on how one handles data after observing an IE and is one of the four components in
defining the estimand.
As discussed above, the trimmed means can be used as a composite approach, whereby IE that lead to missing data
- and potentially others - are ranked poorly and trimmed out of the analysis. The resulting composite estimand can be
thought of as a measure of treatment difference that is penalized by the amount of dropout in each arm. This penalty
comes by placing the IE towards the poor end of the distribution irrespective of if the unobserved data are MAR or MNAR.
In other words, they are ranked as the worst outcome even if their outcome would not have been poor had they continued
in the trial. This type of estimand seems ideal for IE such as adverse events that outweigh the benefit of treatment or
death. To estimate this composite estimand, the location family and strong MNAR assumptions do not need to hold.
Should these assumptions be realistic however, the opportunity arises to use the trimmed means approach to estimate two
other types of estimands: 1) the hypothetical and 2) intention to treat (ITT) estimands.
The hypothetical estimand postulates what would have happened had the intercurrent event not occurred and the
patient remained on treatment for the duration of the trial. Even if post IE data is collected, it is discarded and treated
as missing data. For the ITT estimand the IE is irrelevant, and one is interested in data that occur after the patient
discontinues treatment. If this post IE data is not missing, it is used as a valid endpoint in the analysis. Both the ITT
and hypothetical estimands are estimable using the trimmed means approach if the strong MNAR and location family
assumptions of Theorem 1 hold. The difference between using the trimmed means approach for the hypothetical and ITT
estimands is that the assumptions are made on different counterfactuals that are determined by whether or not treatment
is continued post-IE. It seems more likely that the location family assumption in particular would hold for the hypothetical
estimand, especially when the drug has an additive effect. The strong MNAR assumption seems more likely for the ITT
estimand, but is ultimately based on the process generating the missing data. In addition, if information is collected on
the reasons for missing data, and if some of these missing data can be assumed to be MAR and other strong MNAR then
one could use a combination of multiple imputation and trimmed means to estimate these estimands.
4 Numerical Studies
4.1 Simulation Objectives
Numerical studies herein evaluate the finite sample properties of the trimmed means approach in estimating treatment
efficacy under various missing data generating mechanisms. The simulation presented is motivated by the design of Wang
et al. [11]. This earlier work is extended in a number of ways. Firstly, a comparison to MI under the various missing
data generating mechanisms of the simulation is demonstrated. Additionally, when there exists a mixture of missing data
types the combination approach is evaluated and compared to applying the trimmed means approach and MI globally.
Furthermore, the relationship between bias and violation of the strong MNAR assumption of theorem 1 is considered
under different MNAR scenarios. Lastly, the choice of α is explored. The comparison of trimmed means to MI as well
as the combination approach would not be possible without Theorem 1 because it demonstrates that the approaches can
estimate the same estimand. Data are imputed using the mice package in R, which leverages the same methodology used
by PROC MI in SAS [16].
4.2 Simulation Design
We design the study using four different ways to generate the missing data: a) Missing Completely at Random (MCAR),
b) Missing at Random (MAR), c) Missing Not at Random (MNAR), and d) a mixture of all three types. Figure 1 displays
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the causal diagrams for these simulation designs using the m-graphs of Pearl [17].
Figure 1: m-graphs for scenarios A, B, C, and D of the numerical study
In these diagrams A represents a binary indicator for treatment, Y a continuous clinical endpoint of the study, and
RY a binary indicator variable that is equal to 1 if Y is observed and 0 if Y is missing. Variable Y ∗ is the observed
outcome, and its partially filled in node on the graph indicates that it has some missing values. Filled in nodes represent
fully observed variables (i.e. A and RY ). Nodes that are not filled in represent unobserved variables (i.e. Y ). The arrows
in these graphs make explicit the assumptions about which variables have a causal effect on missingness.
We use a study sample size of N = 100 (n = 50 per treatment arm) in each of the four scenarios. Each scenario was
replicated K = 5000 times. The α parameter that determines which percentile to trim in the analysis is chosen adaptively,
unless stated otherwise. The upper part of the distribution is trimmed, corresponding to lower values reflecting better
outcomes. The underlying model for the continuous outcome remains the same in all simulations:
Y = β0 + βAA+ 
Y is the continuous outcome variable and A is the binary variable representing experimental treatment if 1 and
reference treatment if 0. Here, the error term is normally distributed  ∼ N(0, σ2). The goal is to estimate βA , the
difference of the means between treatments. In all scenarios, the values of the parameters for the outcome model are
β0 = −1, βA = −1, σ = 1.5. We chose σ = 1.5 to obtain a benchmark ~90% power in a one-sided t-test when there is no
missing data.
The missing data in outcome Y were generated via the following logit model:
Pr(RY = 1|A, Y ) = logit−1(α0 + αAA+ αY Y )
Where RY is the binary variable indicating that Y has been observed if equal to 1. In this model, setting parameters
αA = αY = 0 corresponds to MCAR because the missing values are unrelated to treatment or outcome. Setting parameter
αY = 0 corresponds to MAR because the missing values are only dependent on the observed values and not the unobserved
outcome. If αY 6= 0 then the model represents an MNAR missing data generating mechanism.
4.3 Simulation Results
(a) MCAR
In the MCAR setting the α0 parameter is set to values of 2.94, 2.20, 1.74, and 1.39 to induce missing data rates of 5,
10, 15, and 20 percent while keeping αA = αY = 0. The missing data rates are the same on average in each arm since
unobserved outcomes are completely random.
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Missing Rate, % Trimmed Means
A = 1 A = 0 Exp Ref Diff (% bias) Coverage Power
5 5 -2.17 -1.17 -1.00 (0%) 0.96 0.86
10 10 -2.16 -1.16 -1.00 (0%) 0.96 0.83
15 15 -2.15 -1.16 -1.00 (0%) 0.96 0.80
20 20 -2.39 -1.39 -1.00 (0%) 0.96 0.70
Table 1: Trimmed Means with MCAR
Under a completely random missing data generating mechanism (MCAR), the trimmed means approach estimates the
true treatment difference without bias and with appropriate coverage even as the proportion of data missing varies (Table
1). As expected, power decreases as the amount of data not trimmed decreases. MI performed similarly in that bias and
coverage were accurate (Table 2). However, as the amount of missing data increases, power does not deteriorate as quickly
using MI than when using trimmed means. This is because the trimmed means approach performs inference on the subset
of the observations post-trimming and thus uses a smaller effective sample size.
Missing Rate, % Multiple Imputation (MI)
A = 1 A = 0 Exp Ref Diff (% bias) Coverage Power
5 5 -2.00 -1.00 -1.00 (0%) 0.94 0.89
10 10 -2.00 -1.00 -1.00 (0%) 0.94 0.87
15 15 -1.99 -1.00 -0.99 (1%) 0.94 0.84
20 20 -1.99 -1.01 -0.99 (1%) 0.94 0.82
Table 2: Multiple Imputation with MCAR
(b) MAR
In the MAR setting, we first set the αA parameter to values of -8.61, -8.27, -7.80, and -7.06 to induce missing data rates
of 20, 15, 10, and 5 percent in the experimental arm while keeping αY = 0 and α0 = 10 in order to maintain all outcomes
observed in the reference arm. Next, we set αY = 0 and αA = 10 in order to fully observe outcomes in the experimental
arm while varying α0 to values of 2.94, 2.20, 1.73, and 1.39 to induce missing data rates of 5, 10, 15, and 20 percent in
the reference arm.
Missing Rate, % Trimmed Means
A = 1 A = 0 Exp Ref Diff (% bias) Coverage Power
20 0 -1.99 -1.51 -0.48 (52%) 0.74 0.22
15 0 -2.00 -1.41 -0.59 (40%) 0.81 0.37
10 0 -2.00 -1.28 -0.72 (28%) 0.88 0.54
5 0 -2.00 -1.15 -0.84 (16%) 0.93 0.74
0 5 -2.16 -1.01 -1.15 (-15%) 0.95 0.95
0 10 -2.28 -1.00 -1.28 (-28%) 0.90 0.97
0 15 -2.40 -1.00 -1.40 (-20%) 0.85 0.98
0 20 -2.51 -1.00 -1.51 (-51%) 0.77 0.99
Table 3: Trimmed Means with MAR
As expected, the trimmed means estimator is biased in all scenarios when the missing data is truly MAR (Table 3).
The bias increases when the fraction of missing data increases. The direction of the bias is positive when the placebo arm
has more missing data and negative when the active arm has more missing data. This directionality of the bias has an
impact on power, with more MAR data in the active arm leading to a drastic decrease in power and more MAR data in
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the placebo arm causing unreasonably high power. The trimming is directional as all missing values are placed at the poor
end of each respective treatment distribution when in reality under MAR they come from all areas of the distribution. MI
obtains valid estimation in this setting as it was designed explicitly for situations where data are MAR (Table 4).
Missing Rate, % Multiple Imputation (MI)
A = 1 A = 0 Exp Ref Diff (% bias) Coverage Power
20 0 -1.99 -1.00 -0.99 (-1%) 0.94 0.86
15 0 -2.00 -1.00 -1.00 (0%) 0.94 0.88
10 0 -2.00 -1.00 -1.00 (0%) 0.95 0.89
5 0 -1.99 -1.00 -1.00 (0%) 0.95 0.91
0 5 -2.00 -1.00 -1.00 (0%) 0.94 0.90
0 10 -2.00 -1.00 -1.00 (0%) 0.95 0.90
0 15 -2.00 -1.01 -1.00 (0%) 0.95 0.88
0 20 -2.00 -1.01 -1.00 (0%) 0.94 0.86
Table 4: Multiple Imputation with MAR
(c) MNAR
In the MNAR setting, the αY parameter was set to values of -1, -2.5, -5, and -10 causing higher values of Y to be more
likely to be missing while keeping α0 = 2.85 and αA = 0. Here, αY is negative because a decrease in Y reflects a better
outcome. This setup induces missing data rates in the experimental vs reference arms of 2 vs 5, 3 vs 10, 5 vs 15, and
7 vs 20 respectively. The missing data are not simulated strictly as strong MNAR but a general MNAR missing data
mechanism.
Missing Rate, % Trimmed Means
A = 1 A = 0 Exp Ref Diff (% bias) Coverage Power
2 5 -2.14 -1.11 -1.04 (-4%) 0.96 0.90
3 10 -2.28 -1.26 -1.02 (-2%) 0.96 0.90
5 15 -2.41 -1.41 -1.00 (0%) 0.96 0.90
7 20 -2.51 -1.51 -1.00 (0%) 0.95 0.89
Table 5: Trimmed Means with MNAR
The trimmed means approach is fairly unbiased, obtains ideal coverage, and maintains its power in the MNAR setup
as the amount of missing data increases (Table 5). While the marginal means in each arm are biased, the means in each
arm increase at equal rates and keep the estimate of their difference unbiased. Multiple imputation increases bias, reduces
coverage of the true effect, and loses power as the fraction of MNAR data increases (Table 6).
Missing Rate, % Multiple Imputation (MI)
A = 1 A = 0 Exp Ref Diff (% bias) Coverage Power
2 5 -2.10 -1.10 -1.04 (-4%) 0.95 0.92
3 10 -2.14 -1.26 -1.02 (-2%) 0.93 0.88
5 15 -2.19 -1.41 -1.00 (0%) 0.87 0.81
7 20 -2.22 -1.52 -1.00 (0%) 0.79 0.74
Table 6: Multiple Imputation with MNAR
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(d) Mixture: MCAR, MAR, and MNAR
Having a mixture of reasons for missing data reflects the information one would have in a closely monitored clinical trial.
In many trials, data are missing for a combination of reasons such as lack of efficacy, intolerability, and administrative
reasons. In order to generate such data the deletion strategies used in the previous three sections are combined. MNAR
data (R3) were deleted first at rates of 2 vs 5, 3 vs 10, 5 vs 15, and 7 vs 20 in the experimental vs reference arms
respectively. MAR data (R2) were then generated in the experimental group at rates of 23, 17, 10, and 3. MCAR data
(R1) were generated at a rate of 5 percent in each arm. Overall, the missing data rates in the four mixture scenarios in
the experimental vs reference arms are 10 vs 30, 15 vs 25, 20 vs 20, and 15 vs 25 respectively.
Missing Rate, % Trimmed Means
Trt R1 R2 R3 Overall Exp Ref Diff (% bias) Coverage Power
A = 1 5 23 2 30 -2.05 -1.65 -0.40 (60%) 0.71 0.13
A = 0 5 0 5 10
A = 1 5 17 3 25 -2.12 -1.55 -0.56 (44%) 0.80 0.30
A = 0 5 0 10 15
A = 1 5 10 5 20 -2.24 -1.47 -0.77 (23%) 0.90 0.56
A = 0 5 0 15 20
A = 1 5 3 7 15 -2.48 -1.54 -0.93 (7%) 0.94 0.78
A = 0 5 0 20 25
Table 7: Trimmed Means with a Mixture of Missing Data Types
Missing Rate, % Multiple Imputation (MI)
Trt R1 R2 R3 Overall Exp Ref Diff (% bias) Coverage Power
A = 1 5 23 2 30 -2.04 -1.13 -0.91 (9%) 0.92 0.79
A = 0 5 0 5 10
A = 1 5 17 3 25 -2.10 -1.31 -0.79 (21%) 0.87 0.73
A = 0 5 0 10 15
A = 1 5 10 5 20 -2.14 -1.41 -0.73 (27%) 0.83 0.70
A = 0 5 0 15 20
A = 1 5 3 7 15 -2.20 -1.54 -0.66 (34%) 0.75 0.66
A = 0 5 0 20 25
Table 8: Multiple Imputation with a Mixture of Missing Data Types
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Missing Rate, % Trimmed Means + MI
Trt R1 R2 R3 Overall Exp Ref Diff (% bias) Coverage Power
A = 1 5 23 2 30 -2.17 -1.14 -1.03 (-3%) 0.92 0.88
A = 0 5 0 5 10
A = 1 5 17 3 25 -2.32 -1.31 -1.01 (-1%) 0.93 0.88
A = 0 5 0 10 15
A = 1 5 10 5 20 -2.42 -1.42 -1.00 (-0%) 0.94 0.88
A = 0 5 0 15 20
A = 1 5 3 7 15 -2.53 -1.54 -0.99 (1%) 0.94 0.89
A = 0 5 0 20 25
Table 9: Trimmed Means + MI with a Mixture of Missing Data Types
In the mixture setting, the performance of trimmed means applied globally is directly related to the proportion of MAR
missing data (Table 7). This fraction of MAR data decreases across the four scenarios and consequently bias, coverage,
and power improve across the scenarios. Contrarily, MI applied globally performs well with a large fraction of MAR data
and its performance weakens as the proportion of MNAR data increases (Table 8). The combination of trimmed means
and MI exhibits improved bias, coverage, and power as compared to each method applied individually (Table 9). Bias is
at most 3%, no matter the variation in the fraction of missing data due to MAR and MNAR. Coverage and Power are
near the optimal 0.95 and 0.90.
(e) Choice of α and Strong MNAR Assumption
The analyst chooses α- the proportion trimmed from each treatment arm – which can be set to any value above the
maximum proportion of missing data between the two arms. For all previous simulations the value of α was chosen
adaptively. Herein, the adaptive choice of α is compared to a fixed choice where α = 0.5. In addition, to investigate the
strong MNAR assumption of Theorem 1, the percent of missing values that would have fallen below the trim point had
they been observed is calculated for each scenario. The adaptive and fixed α approaches are evaluated under 10 different
MNAR data generating mechanisms using the same logit model as before. The αY parameter was set to values of -0.5,
-1, -1.5, -2, -2.5, -3, -4, -5, -7.5 and -10 while keeping α0 = 2.85 and αA = 0. Rates of missing data and results are shown
in Table 10.
Missing Rate, % Adaptive α Fixed α = 0.5
A = 1 A = 0 Diff (% bias) sMNAR SD MSE Diff (% bias) sMNAR SD MSE
3 4 -1.038 (-3.8%) 11.4% 0.321 0.104 -1.015 (1.5%) 74.6% 0.355 0.126
2 5 -1.038 (-3.8%) 28.2% 0.313 0.100 -1.012 (1.2%) 91.1% 0.352 0.124
2 7 -1.032 (3.2%) 45.9% 0.310 0.097 -1.009 (0.9%) 97.0% 0.351 0.123
3 8 -1.025 (2.5%) 60.6% 0.309 0.096 -1.008 (0.8%) 99.1% 0.351 0.123
3 10 -1.019 (1.9%) 70.3% 0.308 0.095 -1.008 (0.8%) 99.6% 0.351 0.123
3 11 -1.015 (1.5%) 76.4% 0.308 0.095 -1.007 (0.7%) 99.8% 0.350 0.123
4 14 -1.003 (0.3%) 83.8% 0.314 0.099 -0.999 (0.1%) 100.0% 0.356 0.127
5 15 -1.002 (0.2%) 87.9% 0.312 0.098 -1.003 (0.3%) 100.0% 0.355 0.126
6 18 -0.998 (0.2%) 93.4% 0.314 0.099 -1.003 (0.3%) 100.0% 0.355 0.126
7 20 -0.995 (0.5%) 95.7% 0.313 0.098 -1.001 (0.1%) 100.0% 0.351 0.123
Table 10: Comparison of Adaptive and Fixed α
Overall, both the fixed and adaptive α accurately estimate the true difference in treatment effects (βA = −1). As
αY moves further from 0, the percentage of missing values falling below the trim point (i.e. sMNAR) increases. As a
consequence, bias decreases which is consistent with the theoretical result of Theorem 1. Unlike in imputation, bias when
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using trimmed means is not directly related to the fraction of missing data, but rather due to sMNAR. Thus, it is possible
to observe lower bias despite larger amounts of missing data, as is demonstrated here. The fixed α approach consistently
has a higher sMNAR than the adaptive approach. This explains why using the fixed α has lower bias in all scenarios: the
underlying missing values have a higher likelihood of falling below the more extreme trimming quantile. Using the adaptive
α has a smaller variance than the fixed α because the adaptive approach trims the least amount of data possible. The
smaller variance of the adaptive approach translated to a smaller MSE than the fixed approach despite the fixed approach
having less bias. This simulation highlights the bias vs variance tradeoff associated with increasing the percentage of data
trimmed.
5 Discussion
Our work extends the utility of the trimmed means approach for missing data in two key ways: 1) It determines sufficient
conditions for which the trimmed means approach can identify the estimand for the population treatment effect; and 2)
It demonstrates that when different types of missing data are present and can be distinguished, one could combine the
trimmed means approach with multiple imputation to improve estimation.
The trimmed means approach was originally designed to estimate a unique estimand: the treatment difference in the
best (100 × α) % of patients of each arm. The work herein allows us to view the trimmed means approach in a different
way, not a method estimating a unique estimand, but a method that targets the usual estimand of a clinical trial where
accuracy depends on how well the assumptions are satisfied.
Missing data inferences are not possible without assumptions. The strong MNAR assumption, similar to the MAR
assumption, is untestable. It is a conservative assumption that assumes every missing value falls below the trimming
quantile. It would be rare for this assumption to hold perfectly; however, when applied to dropouts reporting loss of
efficacy, where poor outcomes are the primary cause of dropout, the assumption may hold for enough of the missing data
to justify adopting the trimmed means approach. Also the numerical studies show that the trimmed means estimator can
still perform well under MNAR scenarios that are not explicitly strong MNAR. Thus, the assumption may be robust to
slight deviations. One interesting paradox is that while trimming more data leads to a loss in efficiency, theoretically it
allows the strong MNAR assumption to become more plausible since missing values are then more likely to be trimmed. The
simulation comparing a fixed to adaptive choice of α demonstrates this. This bias/variance trade off should be considered
when choosing the value of α. The location shift assumption may be more realistic, is testable among the observed values,
and is often assumed in many statistical methods. In practice, the untrimmed fractions of the distributions for each
treatment arm of the study should be compared using a qq-plot to assess the validity of this assumption. Of course
should neither the location family nor the strong MNAR assumptions be plausible, the trimmed means approach can
still be useful in estimating the original composite estimand in the sub-population of the trial for which it was originally
developed.
This research highlights the importance for administrators and physicians conducting clinical trials to document the
reasons for dropout. If close collaboration between statisticians and clinicians can inform which dropouts are MCAR,
MAR, or MNAR then analysts may have a combination of data that can be imputable and other data that should be
trimmed away using the trimmed means approach. This combination approach can protect analysts from penalizing
themselves using trimmed means globally for all missing data but also respects the assumption that patients may drop
out of the trial due to poor health outcomes. If a fraction of dropouts are missing because of factors unrelated to their
unobserved outcomes (MAR), the bias and loss of power using trimmed means for all dropouts can be drastic. Choosing
which missing data to treat as MAR or MNAR will vary from trial to trial, and will also be dependent on the particular
estimand of interest. Clinical input is crucial for the mixture approach to be effective. One limitation of the combination
approach is that MNAR dropouts must precede MAR dropouts; otherwise the complete cases leveraged for imputations
may have a different outcome distribution than the MAR outcomes.
The trimmed means approach is a creative solution to estimating treatment effects in a clinical trial when missing
data can safely be assumed to be due to poor outcomes. As is the case in any missing data analysis, especially those with
MNAR data, no analytical method replaces a good sensitivity analysis to determine the plausible range of what could
have happened. While no method can fully or confidently rectify the issues caused by missing data, a combination of
multiple imputation and/or trimmed means could be useful when the assumptions of both methods are satisfied.
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Appendix: Proofs
Proof of Theorem 1.
Consider counterfactuals Y1 and Y0 with absolutely continuous distribution functions f1(y) and f0(y) respectively both
defined over a common domain (−∞,∞). Here, Ra is a binary indicator of Ya being observed or missing. Here, binary
treatment a ∈ {0, 1} determines which of the two counterfactuals is observed and is intervened on through randomization.
Lastly consider the transformation of counterfactual Ya such that:
Ua =
{
Ya if Ra = 1
min(Ya|Ra = 1)−  if Ra = 0
for  > 0
There exist two sufficient conditions in order to prove the equality of the trimmed means estimand and treatment
difference in the whole population. The first condition – the location family assumption - is that the distribution of
potential outcomes from the experimental group Y1 ∼ f1(y) is in the same location family as the distribution of potential
outcomes from the reference group Y0 ∼ f0(y). Consider some constant ∆ thenf0(y) = f1(y+∆). If two distributions are a
location shift of one another then E[Y1] = E[Y0]+∆ because the mean is the location parameter of a distribution. Also, note
that as a consequence all quantiles of these distributions are a location shift of one another i.e. F−10 (α)+∆ = F
−1
1 (α). The
second condition – strong MNAR assumption - is that all missing values fall below the point at which the distributions
are trimmed, i.e. Ya|Ra = 0 < F−1a (α). The strong MNAR assumption ensures that the composite outcome Ua is
trimmed at the same value as Ya for all percentiles above the maximum rate of missing data between the two arms,
i.e. F−1Ua (α) = F
−1
a (α)∀α : α > Pr[Ra = 0]. Leveraging both assumptions we can demonstrate the equality of the two
estimands:
E[U1|U1 > F−1U1 (α)]− E[U0|U0 > F−1U0 (α)] = E[Y1|Y1 > F−11 (α)]− E[Y0|Y0 > F−10 (α)]
=
1
1− α
∫ ∞
F−11 (α)
yf1(y)dy − 1
1− α
∫ ∞
F−10 (α)
yf0(y)dy
=
1
1− α
[∫ ∞
F−11 (α)
yf1(y)dy −
∫ ∞
F−10 (α)
yf0(y)dy
]
=
1
1− α
[∫ ∞
F−11 (α)
yf1(y)dy −
∫ ∞
F−10 (α)
yf1(y + ∆)dy
]
=
1
1− α
[∫ ∞
F−11 (α)
yf1(y)dy −
∫ ∞
F−11 (α)
(x−∆)f1(x)dx
]
x = y + ∆, dy = dx
=
1
1− α
[∫ ∞
F−11 (α)
yf1(y)dy −
∫ ∞
F−11 (α)
xf1(x)dx+ ∆
∫ ∞
F−11 (α)
f1(x)dx
]
=
1
1− α
[
∆
∫ ∞
F−11 (α)
f1(x)dx
]
=
1
1− α [∆ [1− α]]
= ∆
= E[Y0]− E[Y0] + ∆
= E[Y1]− E[Y0]
Which completes the proof.
Proof of Theorem 2.
Consider two distributions F1(·) and F0(·) which are absolutely continuous distribution functions defined over a common
domain (−∞,∞). Also, both distributions have an expectation and that expectation is finite. Assume that the differences
between the α-trimmed means are the same constant ∆ ∈ R for all α ∈ [0, 1] that is:
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E[Y1|Y1 > F−11 (α)]− E[Y0|Y0 > F−10 (α)] = ∆
E[Y0|Y0 > F−10 (α)] = E[Y1|Y1 > F−11 (α)]−∆
1
1− α
∫ ∞
F−10 (α)
yf0(y)dy =
1
1− α
∫ ∞
F−11 (α)
yf1(y)dy −∆
1
1− α
∫ ∞
F−10 (α)
yf0(y)dy =
1
1− α
∫ ∞
F−11 (α)
yf1(y)dy − (1− α)
(1− α)∆
1
1− α
∫ ∞
F−10 (α)
yf0(y)dy =
1
1− α
∫ ∞
F−11 (α)
yf1(y)dy − 1
(1− α)∆
∫ ∞
F−11 (α)
f1(y)dy
1
1− α
∫ ∞
F−10 (α)
yf0(y)dy =
1
1− α
[∫ ∞
F−11 (α)
yf1(y)dy −
∫ ∞
F−11 (α)
∆f1(y)dy
]
1
1− α
∫ ∞
F−10 (α)
yf0(y)dy =
1
1− α
[∫ ∞
F−11 (α)
(y −∆)f1(y)dy
]
1
1− α
∫ ∞
F−10 (α)
yf0(y)dy =
1
1− α
[∫ ∞
F−11 (α)−∆
xf1(x+ ∆)dx
]
x = y −∆, dx = dy∫ ∞
F−10 (α)
yf0(y)dy =
∫ ∞
F−11 (α)−∆
xf1(x+ ∆)dx
At this stage perform the substitution of y = F−10 (β), dβ = f0(y)dy for the integral on the left side of the equation
and x = F−11 (β)−∆, dβ = f(x+ ∆)dx for the integral on the right side of the equation such that:
∫ 1
α
[F−11 (β)−∆]dβ =
∫ 1
α
F−10 (β)dβ
d
dα
∫ 1
α
[F−11 (β)−∆]dβ =
d
dα
∫ 1
α
F−10 (β)dβ
−[F−11 (α)−∆] = −F−10 (α), α ∈ (0, 1)
F−11 (α)−∆ = F−10 (α)
∫ 1
α
F−10 (β)dβ =
∫ 1
α
[F−11 (β)−∆]dβ
d
dα
∫ 1
α
F−10 (β)dβ =
d
dα
∫ 1
α
[F−11 (β)−∆]dβ
−F−10 (α) = −[F−11 (α)−∆], α ∈ (0, 1)
F−10 (α) = F
−1
1 (α)−∆
From here it follows that F1 − ∆ = F0 and it is proven that F1 is a location shift of F0 almost everywhere on the
domain i.e. f0(y) = f1(y + ∆).
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